# Alterity Therapeutics Ltd: overview ATHE · Nasdaq · CIK 1131343 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/athe.md) · [Financials](/companies/athe/financials.md) · [Filings](/companies/athe/filings.md) · [Insiders](/companies/athe/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-06-30) | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.90)](/filings/0001213900-23-072629.md) | [(0.53)](/filings/0001213900-24-082281.md) | [(0.57)](/filings/0001213900-25-082027.md) | [(0.52)](/filings/0001213900-25-082027.md) | [(0.19)](/filings/0001213900-25-082027.md) | | Free cash flow | $m | [(17.3)](/filings/0001213900-23-072629.md) | [(12.4)](/filings/0001213900-24-082281.md) | [(20.0)](/filings/0001213900-25-082027.md) | [(12.6)](/filings/0001213900-25-082027.md) | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Net income: ifrs-full:ProfitLoss. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/athe/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Twin Lakes Capital Management, LLC](/funds/1847794.md) | 2026-06-30 | $747.8k | 139,258 | | Unchanged | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $338.7k | 63,065 | | Added +4,683 | | [GREENLEAF TRUST](/funds/1162170.md) | 2026-06-30 | $332.9k | 62,000 | | Added +30,000 | | [HB Wealth Management, LLC](/funds/1911253.md) | 2026-06-30 | $313.9k | 58,460 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $201.9k | 37,597 | | Added +17,520 | | [BNP PARIBAS FINANCIAL MARKETS](/funds/1166588.md) | 2026-06-30 | $55.0k | 10,239 | | Added +3,430 | | [GAMMA Investing LLC](/funds/2010235.md) | 2026-06-30 | $12.4k | 2,309 | | Added +453 | | [RHUMBLINE ADVISERS](/funds/1115418.md) | 2026-06-30 | $10.8k | 2,009 | | Added +39 | | [Providence Capital Advisors, LLC](/funds/1730814.md) | 2026-06-30 | $1.1k | 200 | | New +200 | | [Integrated Wealth Concepts LLC](/funds/1737109.md) | 2026-06-30 | $392 | 73 | | New +73 | ## Recent filings [All 918 filings](/companies/athe/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-30 | 06:00 ET | [6-K](/filings/0001437749-26-034060.md) | Report of a foreign private issuer, period 2026-10-31 | 0001437749-26-034060 | | 2026-10-23 | 06:03 ET | [6-K](/filings/0001437749-26-033323.md) | Report of a foreign private issuer, period 2026-10-31 | 0001437749-26-033323 | | 2026-10-23 | 06:02 ET | [6-K](/filings/0001437749-26-033320.md) | Report of a foreign private issuer, period 2026-10-31 | 0001437749-26-033320 | | 2026-10-23 | 06:00 ET | [6-K](/filings/0001437749-26-033317.md) | Report of a foreign private issuer, period 2026-10-31 | 0001437749-26-033317 | | 2026-10-21 | 06:01 ET | [6-K](/filings/0001437749-26-033047.md) | Report of a foreign private issuer, period 2026-10-31 | 0001437749-26-033047 | | 2026-10-21 | 06:00 ET | [6-K](/filings/0001437749-26-033045.md) | Report of a foreign private issuer, period 2026-10-31 | 0001437749-26-033045 | | 2026-10-19 | 06:03 ET | [6-K](/filings/0001437749-26-032871.md) | Report of a foreign private issuer, period 2026-10-31 | 0001437749-26-032871 | | 2026-10-09 | 06:00 ET | [6-K](/filings/0001437749-26-032387.md) | Report of a foreign private issuer, period 2026-10-31 | 0001437749-26-032387 | | 2026-10-05 | 06:01 ET | [6-K](/filings/0001437749-26-031946.md) | Report of a foreign private issuer, period 2026-10-31 | 0001437749-26-031946 | | 2026-09-25 | 06:02 ET | [6-K](/filings/0001437749-26-031171.md) | Report of a foreign private issuer, period 2026-09-30 | 0001437749-26-031171 | ## Latest annual report [Form 20-F for the fiscal year ended Jun 30, 2026](/filings/0001437749-26-029135.md), filed Aug 28, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1131343 - Tickers: ATHE, PRNAF - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: C3 - Filer category: Non-accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 06:15 ET. No prices; not investment advice.